查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1980761

2026-2034年全球出血性疾病治疗市场规模、份额、趋势和成长分析报告

Global Bleeding Disorder Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 121 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计出血性疾病治疗市场规模将从 2025 年的 228.6 亿美元成长到 2034 年的 449.1 亿美元，2026 年至 2034 年的复合年增长率为 7.79%。

随着全球对出血性疾病（BGM）的认知和诊断水准不断提高，全球出血性疾病市场正稳步成长。出血性疾病，包括血友病和血管性血友病，需要专门的治疗来预防过度出血和控制併发症。确诊患者数量的增加以及医疗服务可近性的提高，都促使人们对有效的治疗方案的需求日益增长。

生物技术和药物研发的进步显着推动了市场扩张。重组凝血因子、基因疗法和缓释药物等创新疗法正在改善患者预后并减少治疗频率。医疗机构和病患权益组织也努力提高大众对出血性疾病的认识，促进早期诊断和更有效的疾病管理。

展望未来，随着先进治疗方法的持续研发，全球出血性疾病治疗市场预计将持续成长。基因疗法和个人化医疗的发展为更有效、更永续的治疗方法创造了新的机会。随着医疗体系诊断能力的提升和治疗可近性的提高，出血性疾病治疗市场预计将稳定扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球出血性疾病治疗市场：依类型划分

  • 市场分析、洞察与预测
  • A型血友病A
  • B型血友病
  • 血管性血友病
  • 其他的

第五章 全球出血性疾病治疗市场：依药物类别划分

  • 市场分析、洞察与预测
  • 血浆衍生凝血因子浓缩物
  • 重组凝血因子浓缩物
  • 去氨加压素
  • 抗纤溶药物
  • 纤维蛋白胶
  • 其他的

第六章 全球出血性疾病治疗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Shire Plc
    • Baxalta
    • Bayer AG
    • Biogen Inc
    • CSL Behring
    • Novo Nordisk
    • Pfizer Inc
    • Grifols SA
    • Octapharma AG
    • Sanofi SA
    • Alnylam Pharmaceuticals Inc
简介目录
Product Code: VMR112115274

The Bleeding Disorder Treatment Market size is expected to reach USD 44.91 Billion in 2034 from USD 22.86 Billion (2025) growing at a CAGR of 7.79% during 2026-2034.

The Global Bleeding Disorder Treatment Market is experiencing steady growth as awareness and diagnosis of bleeding disorders continue to improve worldwide. Bleeding disorders, including hemophilia and von Willebrand disease, require specialized treatments to prevent excessive bleeding and manage complications. The increasing number of diagnosed patients and improved access to healthcare services are contributing to the growing demand for effective treatment options.

Advancements in biotechnology and pharmaceutical development are playing a significant role in market expansion. Innovative therapies such as recombinant clotting factors, gene therapy, and long-acting treatments are improving patient outcomes and reducing the frequency of treatment administration. Healthcare organizations and patient advocacy groups are also working to raise awareness about bleeding disorders, encouraging early diagnosis and better disease management.

Looking forward, the Global Bleeding Disorder Treatment Market is expected to grow due to continued research in advanced therapeutic approaches. The development of gene-based therapies and personalized medicine is creating new opportunities for more effective and long-lasting treatments. As healthcare systems improve diagnostic capabilities and treatment accessibility, the market for bleeding disorder therapies is anticipated to expand steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

By Drug Class

  • Plasma-Derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

COMPANIES PROFILED

  • Takeda Pharmaceutical Company Limited, , Shire Plc, Baxalta, Bayer AG, Biogen Inc, CSL Behring, Novo Nordisk, Pfizer Inc, Grifols SA, Octapharma AG, Sanofi SA, Alnylam Pharmaceuticals Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Von Willebrand Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Plasma-Derived Coagulation Factor Concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Recombinant Coagulation Factor Concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Desmopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Antifibrinolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Fibrin Sealants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Drug Class
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Drug Class
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Drug Class
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Drug Class
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Drug Class
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLEEDING DISORDER TREATMENT INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Shire Plc
    • 8.2.2 Baxalta
    • 8.2.3 Bayer AG
    • 8.2.4 Biogen Inc
    • 8.2.5 CSL Behring
    • 8.2.6 Novo Nordisk
    • 8.2.7 Pfizer Inc
    • 8.2.8 Grifols SA
    • 8.2.9 Octapharma AG
    • 8.2.10 Sanofi S.A
    • 8.2.11 Alnylam Pharmaceuticals Inc